Post-Treatment Lyme Disease Syndrome (PTLDS) Management

Diagnosis and Treatment Approach

• The primary approach for managing PTLDS is symptomatic therapy, as extended antibiotic courses are not recommended due to lack of evidence for benefit and potential harm, according to the Infectious Diseases Society of America 1
• Before establishing a diagnosis of PTLDS, confirm previous Lyme disease diagnosis was accurate, rule out alternative diagnoses, verify that appropriate initial antibiotic therapy was completed, and ensure symptoms began within 6 months after initial Lyme disease treatment, as recommended by the Infectious Diseases Society of America 1
• If new objective manifestations develop, re-treatment with appropriate antibiotics is warranted, according to the Infectious Diseases Society of America 1
• For Lyme meningitis that develops during or after treatment, re-treat with ceftriaxone or comparable parenteral antibiotic, as recommended by the Infectious Diseases Society of America 1
• The treatment approach should be guided by the clinical manifestations, and intravenous ceftriaxone 2 g daily for 2-4 weeks may be necessary for severe cases, as recommended by the CDC 1
• Hospitalization and IV antibiotics may be necessary for symptomatic patients or those with advanced heart block, as recommended by the CDC 1
• The following treatment approaches are recommended for specific manifestations:

1

Risks of Extended Antibiotic Therapy

• Extended antibiotic therapy carries significant risks, including adverse drug reactions, complications from intravenous catheters, development of antibiotic resistance, and unnecessary economic costs, according to the Infectious Diseases Society of America 1
• Multiple controlled trials have shown that extended antibiotic therapy provides no sustained benefit for patients with PTLDS, as stated by the Infectious Diseases Society of America 1
• Extended antibiotic courses for non-specific symptoms are not supported by research, and may lead to unnecessary side effects, as advised by the CDC and the Infectious Diseases Society of America 1, 2

Treatment of Subjective Symptoms

• For patients with only subjective symptoms without objective findings, consider fatigue management with structured exercise programs, sleep hygiene measures, and referral to fatigue management specialists, as well as pain management with non-opioid analgesics, physical therapy, and referral to pain specialists for persistent pain 1
• Cognitive difficulties can be addressed with cognitive rehabilitation strategies and neuropsychological evaluation if severe, while mood disorders can be managed with screening for depression and anxiety, psychiatric referral and treatment, and consideration of antidepressants, particularly when fatigue and depression coexist 1

Diagnostic Testing

• The Centers for Disease Control and Prevention (CDC) recommends a two-tier testing approach, starting with enzyme-linked immunoassay (EIA/ELISA) or immunofluorescence assay (IFA), followed by Western immunoblot if the first tier is positive or equivocal 2
• For illness ≤30 days, testing for both IgM and IgG antibodies is recommended, while for illness >30 days, testing for IgG antibodies only is suggested 2
• Positive IgM Western blot is defined as ≥2 of 3 specific bands (21-24, 39, and 41 kDa), although the exact definition may vary depending on the laboratory 2
• A positive IgG Western blot requires ≥5 of 10 specific bands, and the presence of 6 positive IgG bands exceeds this threshold, confirming past exposure to Borrelia burgdorferi 1, 3
• Antibodies persist for months/years after successful treatment, with low sensitivity (30-40%) during early infection and high specificity (>95%) during all stages of disease 2
• Testing without appropriate pretest probability can lead to false positives, especially in low-risk populations, as stated by the Infectious Diseases Society of America 2

Antibiotic Treatment Regimens

• For non-pregnant and non-lactating patients, doxycycline 100 mg orally twice daily for 14-21 days or amoxicillin 500 mg orally three times daily for 14-21 days or cefuroxime axetil 500 mg orally twice daily for 14-21 days can be used, with the American College of Rheumatology and Infectious Diseases Society of America recommending these regimens 4
• If pregnant or lactating, the Infectious Diseases Society of America recommends avoiding doxycycline and using amoxicillin or cefuroxime instead 1
• For children under 8 years, the American Academy of Pediatrics recommends avoiding doxycycline and using amoxicillin 50 mg/kg/day in 3 divided doses (max 500 mg per dose) 1
• Alternative treatment options include amoxicillin 500 mg orally three times daily for 14-21 days and cefuroxime axetil 500 mg orally twice daily for 14-21 days, as recommended by the CDC 1
• Prophylactic single-dose doxycycline may be considered for high-risk tick bites within 72 hours, as suggested by the CDC and supported by the Infectious Diseases Society of America 4, 2

Monitoring and Re-Evaluation

• The American College of Rheumatology recommends monitoring for resolution of symptoms during and after treatment, and considering IV ceftriaxone if neurologic symptoms develop (such as meningitis, encephalitis, or radiculopathy) 4
• If cardiac symptoms develop (such as palpitations, chest pain, or syncope), the American Heart Association recommends obtaining an ECG and considering hospitalization if PR interval >300 ms or other arrhythmias present, with guidance from the Infectious Diseases Society of America and American College of Rheumatology 4, 1
• Most patients respond well to appropriate antibiotic therapy, with resolution of symptoms within weeks to months, according to the Infectious Diseases Society of America and American College of Rheumatology 4, 1
• If symptoms worsen despite appropriate therapy, or if new objective neurological findings develop, or if signs of cardiac involvement appear (dyspnea, palpitations, syncope), or if arthritis develops and persists after treatment, the American College of Rheumatology and Infectious Diseases Society of America recommend re-evaluation 4, 1

Coinfections and Other Considerations

• Consider testing for Babesia microti or Anaplasma phagocytophilum in patients with more severe initial symptoms, high-grade fever persisting >48 hours despite appropriate therapy, or unexplained leukopenia, thrombocytopenia, or anemia, as recommended by the CDC and the MMWR Recommendations and Reports 1, 5
• Positive serology alone does not indicate active infection, and clinical correlation is essential, as recommended by the CDC and the Infectious Diseases Society of America 6, 2
• Misinterpreting persistent antibodies can lead to unnecessary treatment, as antibodies can persist for months/years after successful treatment 2
• Overlooking coinfections such as Babesia microti or Anaplasma phagocytophilum can lead to delayed or inadequate treatment, especially in patients with severe initial symptoms or high-grade fever persisting >48 hours despite therapy 2
• Relying on PCR or culture alone is not recommended due to limited sensitivity, as stated by the Centers for Disease Control and Prevention (CDC) 2